Ftse Mib
35.398,82
-0,03%
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
NASDAQ
16.685,97
-0,07%
Bitcoin
66.822,41
-0,39%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Rxi Pharmaceuticals Corp. (MM) (RXII) Rxi Pharmaceuticals Corp. (MM) (RXII) Notizie

RXII

RXI Pharmaceuticals Corporation (RXII)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:RXII
DataOraFonteTitoloSimboloCompagnia
15/02/201913:15PR Newswire (US)Phio Pharmaceuticals Appoints Gerrit Dispersyn as New Chief Executive Officer Effective March 1NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
10/12/201815:35Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
19/11/201823:52Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
14/11/201813:10PR Newswire (US)RXi Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Corporate HighlightsNASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
14/11/201813:08Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
07/11/201813:05PR Newswire (US)RXi Pharmaceuticals to Present New Data Demonstrating the Ability of sd-rxRNA to Enhance NK Cell Activity for Adoptive Cell T...NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
06/11/201813:05PR Newswire (US)RXi Pharmaceuticals to Webcast Third Quarter 2018 Financial Results on Wednesday, November 14, 2018NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
10/10/201820:00Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
03/10/201822:31PR Newswire (US)RXi Pharmaceuticals Announces Closing Of $15 Million Underwritten Public OfferingNASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
02/10/201823:32Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
02/10/201823:30Edgar (US Regulatory)Post-effective Amendment Filed Solely to Add Exhibits to a Registration Statement (pos Ex)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
01/10/201812:39Edgar (US Regulatory)Registration of Additional Securities (up to 20%) (s-1mef)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
01/10/201812:36Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
01/10/201812:10PR Newswire (US)RXi Pharmaceuticals Announces Pricing Of $15 Million Upsized Underwritten Public OfferingNASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
28/09/201812:14Edgar (US Regulatory)Securities Registration Statement (s-1/a)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
26/09/201814:00PR Newswire (US)RXi Pharmaceuticals to Present New Data from its Immuno-Oncology Program Using sd-rxRNA Therapeutic Compounds Targeting Intra...NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
14/09/201823:48Edgar (US Regulatory)Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
31/08/201823:32Edgar (US Regulatory)Securities Registration Statement (s-1)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
28/08/201815:15PR Newswire (US)RXi Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment ConferenceNASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
24/08/201823:04Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
17/08/201823:02Edgar (US Regulatory)Amended Small Company Offering and Sale of Securities Without Registration (d/a)NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
15/08/201815:25PR Newswire (US)RXi Pharmaceuticals and Karolinska Institutet Enter into Collaboration to Develop sd-rxRNA Compounds to Improve Functionality...NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
14/08/201815:15PR Newswire (US)RXi Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Corporate HighlightsNASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
07/08/201813:15PR Newswire (US)RXi Pharmaceuticals to Webcast Second Quarter 2018 Financial Results on Tuesday, August 14, 2018NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
02/08/201815:25PR Newswire (US)RXi Pharmaceuticals Granted Patents for sd-rxRNA Technology Strengthening Intellectual Property Estate in Europe and JapanNASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
01/08/201815:25PR Newswire (US)RXi Pharmaceuticals Announces Positive Results From Phase 1/2 Trial With RXI-109 For Retinal ScarringNASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
28/06/201814:00PR Newswire (US)BioAxone BioSciences Awarded $1.1 Million Phase 2 SBIR Funding for Continued Development of sd-rxRNA Drug Candidate for the T...NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
18/05/201817:58PR Newswire (US)RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with Samcyprone™ for the Treatment of Common WartsNASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
11/05/201813:05PR Newswire (US)RXi Pharmaceuticals Enters into Material Transfer Agreement with Iovance Biotherapeutics to Study its Self-Delivering RNAi Te...NASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
10/05/201813:05PR Newswire (US)RXi Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Corporate HighlightsNASDAQ:RXIIRxi Pharmaceuticals Corp. (MM)
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:RXII

La tua Cronologia

COIN
SGOGBP
EU
MLSEQ
Sequa Petroleum NV
UNSW
MKRETH
Maker
BIT
UB3CVS
Unicredit Bank
TG
AOX
Alstria Office REIT
BITV
STXEUR
Stacks
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network